Overview

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fluticasone
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Glycopyrrolate
Salmeterol Xinafoate